REG-4basebio Plc: Final Results and Notice of AGM
Today 07:05
4basebio PLC
("4basebio" or the "Company")
Final Results and Notice of AGM
CAMBRIDGE, UK – 20 May
2026
– 4basebio plc (AIM: 4BB),
a company pioneering an
enzymatically-produced DNA technology serving the next generation genetic
medicines markets, announces its audited final results for the year ended 31
December 2025.
FINANCIAL HIGHLIGHTS
*
Revenue for the period of £1.7 million
(FY 2024: £0.9 million), representing growth of 81%, with revenue from
clinical stage projects contributing £1.1 million (FY 2024: £0.5 million),
and DNA sales revenue increasing by 100%
*
Loss for the period of £16.9 million
(FY 2024: £12.3 million), reflecting continued planned investment in
commercial infrastructure, GMP capabilities and product development
*
Cash and cash equivalents of £17.8
million at 31 December 2025 (FY 2024: £34.6 million), with a subsequent €7
million drawdown under the Deutsche Balaton facility in April 2026 providing
the Group with funding into late-2027
OPERATIONAL HIGHLIGHTS
*
Growing commercial momentum with a
diverse and broadened customer base, driven by an expanding product offering
focusing on gene editing, mRNA, viral vectors and DNA vaccines
*
New business pipeline value increased
by 41% from Q3 to Q4 2025, reflecting strong market demand and enhanced
business development focus; approximately half of the pipeline is GMP/HQ
opportunities, with momentum in new business continuing post-year end
*
Receipt of MIA IMP Good Manufacturing
Practice (GMP) certification from the UK’s Medicines and Healthcare Products
Regulatory Agency (MHRA), significantly enhancing the Company’s ability to
support customers through the clinical development lifecycle
*
Tier 1
pharmaceutical partnership commenced, with supply of enzymatically-produced
DNA for mRNA vaccine Phase I/II programme
*
Customer base growth to 125+ customers, with four Investigational New Drug
(IND) and Clinical Trial Authorisations (CTAs) supported
*
Further clinical validation achieved through supply of opDNA™ for an mRNA
vaccine trial
*
Appointment of senior, US and
EU-focused commercial team experienced in genetic medicines and CDMO services,
accelerating 4basebio’s business development activity in North America
*
Expansion of intellectual property portfolio to 33 patent families,
reinforcing 4basebio’s market leading position in synthetic DNA
*
Dr Manja
Boerman appointed as Executive Chair, bringing 25 years of experience in
biologics and advanced therapies, including executive roles at Catalent’s
cell, gene, and protein thearpy division, DSM Biologics, and Patheon Biologics
POST-PERIOD END HIGHLIGHTS
*
Senior leadership
team appointed to align 4basebio for acceleration of commercialisation, with
the appointment of Dr Amy Walker as Chief Executive Officer in February 2026
*
Richard Bungay named
Chief Financial Officer with a start date of July 2026
*
Christine Wolosin
promoted to Chief Commercial Officer to lead global Business Development
*
Appointment of Scott
Lorimer, a 30-year veteran of bioprocess development and commercial
manufacturing as Chief Operating Officer, to lead the building of 4basebio’s
commercial infrastructure
-
*
Signed a new multi-year, approximately
seven-figure Clinical Supply Agreement reflecting increased commercial
momentum, as 4basebio’s opDNA® technology will support a Phase II clinical
trial of immunotherapy candidate
Dr
Amy Walker, Chief Executive Officer of
4basebio, commented:
“2025 represented a step-change for the Company, with GMP accreditation, a
growing customer base and commercial appointments underpinning our transition
into a highly commercially focused business. 4basebio’s expertise in
enzymatic DNA manufacturing offers superior safety and efficacy compared with
plasmid DNA, and we are seeing more advanced therapy developers recognising
these advantages, underlined by the continued clinical use of our
technology.
“Since taking the role of CEO of 4basebio, I’ve been focused on putting
the right team in place for this commercial phase and I’m excited by the
progress we have achieved. We now have the personnel and infrastructure to
drive delivery. After the period end, we’ve seen this reflected in strong
commercial progress, enabled by a more diverse product offering and
exceptional scientific and commercial teams. We believe 4basebio is extremely
well positioned to benefit from the substantial and growing demand for
synthetic DNA and accordingly we expect to see significant growth in revenues
2026 and beyond.”
Dr Manja Boerman, Executive Chair of 4basebio, added:
“4basebio is at a pivotal point in its development. We have a fantastic team
in place, strengthening the Company’s ability to take advantage of the
growing demand in genetic medicine markets for enzymatic manufacturing
solutions.
“I want to thank our Board and share holders for their continued support. We
are excited about the opportunities ahead and look forward to continuing to
leverage our innovative offering, technical expertise and commercial
infrastructure to drive further market penetration.”
This announcement contains inside information for the purposes of Article 7 of
the UK version of the Market Abuse Regulation (EU) No. 596/2014 (“UK
MAR”), as amended and forming part of UK law by virtue of the European Union
(Withdrawal) Act 2018. Upon publication of this announcement, this inside
information is now considered to be in the public domain.
Investor Presentation
The Company will host a presentation for institutional investors today at
09:00am at the offices of RBC Capital Markets,
100 Bishopsgate, London EC2M
1GT. Investors who would like to attend can register their interest
here
(mailto:mailto:kathryn.deegan@rbccm.com?subject=%20I%20would%20like%20to%20attend%204basebio's%20investor%20event%20today)
.
Annual Reports and Accounts and Notice of Annual General Meeting
The Annual Report and Accounts for the year ended 31 December 2025, together
with Notice of the Company’s Annual General Meeting, which is to be held on
30 June 2026 at 10:00am at the offices of 4basebio plc, are expected to be
uploaded to the Company’s website and posted to shareholders shortly.
The Annual General Meeting will be followed by a presentation from the Company
through the Investor Meet Company platform. Further information will be
provided in due course.
For further enquiries, please contact:
4basebio PLC +44 (0)12 2396 7943
Dr Amy Walker, CEO
Cairn Financial Advisers LLP (Nominated Adviser) +44 (0)20 7213 0880
Jo Turner / Sandy Jamieson / Ed Downes
Cavendish Capital Markets Limited (Joint Broker) +44 (0)20 7220 0500
Geoff Nash / Nigel Birks
RBC Capital Markets (Joint Broker) +44 (0)20 7653 4000
Kathryn Deegan / Matthew Coakes
ICR Healthcare (Media and Investor Relations) +44 (0)203 707 5700
Mary-Jane Elliott / Jessica Hodgson
About 4basebio
4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the
use of synthetic DNA to enable next-generation therapeutics and vaccines.
Through its proprietary enzymatic DNA synthesis platform, 4basebio produces
GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability,
overcoming the limitations of plasmid-based systems. The company offers
application-specific DNA constructs tailored to the diverse needs of gene
therapies, genome editing, mRNA production, and DNA vaccines, helping partners
accelerate proof-of-concept studies and reach clinical milestones more
efficiently while maintaining the highest standards of safety and quality. For
more information, visit
www.4basebio.com
.
Joint statement from the Chief Executive Officer and Executive Chair
We are pleased to report on the year ended 31 December 2025, which represented
a pivotal year for 4basebio as we continued our transformation from a
research-focused organisation into a commercially driven enterprise aiming to
deliver synthetic, cell-free DNA as the foundation for every genetic medicine.
While the advanced therapeutics sector faced challenging market conditions
that impacted timelines and funding across the industry, we delivered
significant operational progress that has positioned us strongly for
accelerated growth.
During 2025, we continued to enhance and further innovate our product offering
to address the growing demand of innovators working across multiple modalities
including viral vectors, gene editing, mRNA medicines, DNA and mRNA for
vaccines. These advancements diversified our customer base to more than 125
partners. The broad customer base now spans emerging and established biotechs
and large pharmaceutical organisations. To date, we have supported four
Investigational New Drug (IND) applications and Clinical Trial Authorisations
(CTAs) underscoring our role as a trusted partner in advancing therapeutic
development.
Regulatory Milestone Achievement
In April 2025, we achieved a critical regulatory milestone by securing MIA IMP
Good Manufacturing Practice (GMP) certification from the UK's Medicines and
Healthcare products Regulatory Agency (MHRA). This certification authorises us
to supply GMP-grade synthetic DNA for clinical programmes in advanced
therapies and genetic medicines, cementing our capability to support partners
throughout their entire clinical development lifecycle with premium,
clinical-grade materials.
Continued Clinical Validation
The clinical and commercial validation of our platform reached a significant
milestone in October when a global Tier 1 pharmaceutical partner initiated
patient dosing with an mRNA product utilising our proprietary opDNA® template
in a Phase I/II clinical trial. This achievement, stemming from a supply
agreement established in April 2024, demonstrates the real-world impact and
reliability of our technology.
Strengthening Leadership for Scale
In July 2025, we appointed Manja Boerman as Executive Chairman, a strategic
addition that brings over 25 years of experience building multi-national CDMOs
focused on biologics and advanced therapies. Manja's deep industry expertise
and proven track record in scaling operations will be instrumental as we meet
the escalating demand for our pDNA-free synthetic DNA platform.
In the second half of the year, we established a new global commercial
leadership team under Christine Wolosin, a 25-year life sciences veteran with
exceptional experience building go-to-market operations for manufacturing
services for advanced therapies or genetic medicines. Christine was promoted
to Chief Commercial Officer in March 2026, and has accelerated our North
American and European expansion in Business Development and Marketing
activities leading to significant pipeline growth.
Accelerating Commercial Momentum
Despite market headwinds, particularly from the US administration with
regulatory concerns from FDA leadership and widespread cuts to the National
Institute of Health’s budget, the Company delivered a 100% growth in DNA
sales revenue. The impact of our strategic investments and new leadership
additions became evident in the second half of 2025. Our new business pipeline
value increased by 41% from Q3 to Q4 2025, reflecting strong market demand and
the effectiveness of our enhanced commercial capabilities. This robust
pipeline of pre-clinical and clinical opportunities, which has continued to
expand post-period end, positions 4basebio for rapid commercial and financial
growth in the years ahead.
New Chief Executive Officer and Chief Financial Officer
Post-period end in February 2026, Dr Amy Walker was appointed as Chief
Executive Officer, after more than five years with the business, most recently
as Chief Operating Officer. Amy played a key role in developing the IP
surrounding the DNA platform and its application across the cell and gene
therapy space, alongside scaling 4basebio’s GMP manufacturing capabilities,
strengthening direct engagement with top-tier biopharma customers and
supporting the Company’s growth operationally and strategically. Amy will
lead the Company’s accelerated commercial growth strategy. Amy succeeded
Dr Heikki Lanckriet, Founder of the Company, who has remained on the Board as
a Non-Executive Director.
Following Amy’s transition to the role as CEO, 4basebio announced the
appointment of Scott Lorimer as Chief Operating Officer. Scott brings more
than 30 years’ experience in bioprocess development and scale up and
clinical and commercial manufacturing of biologics and cell and gene therapies
and will be responsible for scaling the Company’s innovative synthetic DNA
platform as our commercial traction continues to accelerate.
Richard Bungay was appointed CFO and will join the business in July 2026.
Richard is an accomplished leader with over 30 years’ senior finance and
strategic experience within the pharmaceutical and biotechnology sector,
leading both public and private companies from research through all clinical
phases, regulatory approval and commercialisation.
Financial performance
Overcoming some of the commercial headwinds arising in 2025 and with the
commercial team demonstrating significant pipeline acceleration, the Group
expects continued strong revenue growth in 2026. The Group expects to remain
loss-making in 2026 and will draw on its cash resources to fund those losses.
Outlook
During 2025
and at the start of 2026, 4basebio has made substantial progress,
positioning
the Company to capitalise on exciting opportunities
ahead as next-generation genetic medicines market continues
its
rapid expansion.
This is shown through
significant
progress both in revenue and the development of its customer pipeline.
Driving growth is the primary focus of the business. While the broader biotech
fundraising environment and evolving US regulatory policies continue to
present variable timelines for projects, the strong growth in commercial
opportunities and pipeline demonstrates the rapidly growing demand for
synthetic DNA whilst commercial visibility steadily improves. As a result, we
anticipate continued acceleration in our pipeline and revenue though 2026 as
clients continue to adopt cell-free DNA in their assets.
To support this commercial trajectory, 2026 will be a year of significant
operational and product development. The Company’s confidence in its
commercial success is underscored by the decision to relocate to a new
innovation hub and manufacturing facility in Cambridge, UK, planned for late
summer 2026, which will significantly expand our production footprint and
increasing customer throughput.
Our vision is to become a worldclass manufacturer focused on delivering
synthetic, cell-free DNA as the foundation for every genetic based medicine.
While we anticipate continued strategic investments in our technologies and
commercial infrastructure, the Board remains highly confident that these
foundational steps will yield substantial, long-term shareholder and
stakeholder value. We expect that our current cash levels will provide the
Group with funding into late-2027.
We would like to take this opportunity to thank our shareholders for their
continued support and our dedicated team for their exceptional work in
delivering this transformational year. We look forward to much progress in the
years ahead.
Dr Manja Boerman Dr Amy Walker
Executive
Chair Chief
Executive Officer
19 May 2026
19 May 2026
Consolidated statement of profit or loss and other comprehensive income
For the year ended 31 December 2025
[in £'000] 2025 2024
Revenues 1,693 933
Cost of goods sold (719) (303)
Gross profit 974 630
Administrative expenses (17,701) (13,866)
Other operating expenses (969) (114)
Other operating income 96 1,308
Operating result (17,600) (12,042)
Finance income 884 140
Finance costs (887) (752)
Loss before tax (17,603) (12,654)
Income tax credit 698 321
Loss for the year (16,905) (12,333)
Loss per share - basic and diluted (in £/share) (1.09) (0.94)
Items that may be reclassified subsequently to profit or loss:
Foreign exchange differences on translation of foreign operations 316 (313)
Total comprehensive loss for the year (16,589) (12,646)
All of the loss for the year is from continuing operations.
Consolidated statement of financial position
As at 31 December 2025
[in £'000] 2025 2024
Assets
Other intangible assets 4,825 3,480
Property, plant and equipment 4,027 4,326
Other non-current assets 33 33
Total non-current assets 8,885 7,839
Current assets
Inventory 657 374
Trade receivables 289 283
Other current assets 1,915 1,627
Cash and cash equivalents 17,803 34,604
Total current assets 20,664 36,888
Total assets 29,549 44,727
Liabilities
Trade payables (1,052) (1,694)
Lease liabilities (130) (41)
Other current liabilities (1,607) (1,383)
Other financial liabilities (39) (147)
Total current liabilities (2,828) (3,265)
Non-current liabilities
Financial liabilities (15,645) (14,294)
Lease liabilities (691) (734)
Other liabilities (274) (54)
Total non-current liabilities (16,610) (15,082)
Total liabilities (19,438) (18,347)
Net assets 10,111 26,380
Equity
Share capital 13,799 13,772
Share premium 37,254 37,250
Capital reserves 14,151 13,864
Foreign exchange reserve (155) (471)
Merger reserve 688 688
Accumulated losses (55,626) (38,723)
Total equity 10,111 26,380
Consolidated statement of changes in equity
For the years ended 31 December 2025 and 31 December 2024
[in £'000] Share capital Share premium Capital reserve FX reserve Merger reserve P&L reserve Total equity
At 1 January 2025 13,772 37,250 13,864 (471) 688 (38,723) 26,380
Loss for the year - - - - - (16,905) (16,905)
FX translation differences - - - 316 - - 316
Shares issued in period (SIP/options) 27 4 - - - - 31
Share-based payment charge - - 288 - - - 288
At 31 December 2025 13,799 37,254 14,151 (155) 688 (55,628) 10,111
At 1 January 2024 11,132 706 13,530 (158) 688 (26,390) (492)
Loss for the year - - - - - (12,333) (12,333)
FX translation differences - - - (313) - - (313)
Shares issued in period 2,640 36,544 - - - - 39,184
Share-based payment charge - - 334 - - - 334
At 31 December 2024 13,772 37,250 13,864 (471) 688 (38,723) 26,380
Consolidated statement of cash flows
For the year ended 31 December 2025
[in £'000] 2025 2024
Cash flows from operating activities
Loss for the year (16,905) (12,333)
Adjustments for:
Tax charge (698) (321)
Tax received 412 117
Depreciation of property, plant and equipment 940 800
Amortisation of capitalised development costs and patents 205 133
Share-based payment charge 288 334
Foreign exchange adjustments 768 (608)
Other operational foreign exchange and non-cash items 411 (101)
Net finance (income)/costs 3 612
Changes in working capital:
(Increase)/decrease in inventories (283) (49)
(Increase)/decrease in trade receivables and other current assets (294) (76)
Increase/(decrease) in trade payables and other current liabilities (437) 748
Net cash flow from operating activities (15,588) (10,744)
Cash flows from investing activities
Investments in property, plant and equipment (458) (697)
Investments in capitalised development and intangible assets (1,181) (874)
Interest received 909 72
Net cash flow from investing activities (730) (1,499)
Cash flows from financing activities
Proceeds from issue of equity (net of expenses) - 38,484
Proceeds from exercise of share options 31 700
Drawdowns under loan facility - 8,800
Repayments under loan facility (274) (3,988)
Lease liability repayments (IFRS 16) (126) (115)
Interest paid (72) (86)
Net cash flow from financing activities (441) 43,795
Net (decrease)/increase in cash and cash equivalents (16,759) 31,552
Foreign exchange differences (42) (17)
Cash and cash equivalents at 1 January 34,604 3,069
Cash and cash equivalents at 31 December 17,803 34,604
Notes to the financial statements
1. General
4basebio PLC (the “Company” or “4basebio”) is registered in England
and Wales with company number 13519889. The Company is domiciled in England
and the registered office of the Company is 25 Norman Way, Over, Cambridge
CB24 5QE. 4basebio PLC is the parent of a group of companies (together, “the
Group”). The Group focuses on life sciences, in particular the development
of synthetic DNA and nanoparticles suitable for inclusion in, or delivery of,
therapeutic payloads for gene therapies and gene vaccines.
The Company trades on London Stock Exchange’s AIM market. The international
securities number (ISIN) for its AIM-traded shares is GB00BMCLYF79; its ticker
symbol is 4BB.L.
The consolidated financial statements of 4basebio PLC and its subsidiaries for
the year ended 31 December 2025 were authorised for issue in accordance with a
resolution of the Directors on 19 May 2026.
2. Basis of preparation
The consolidated financial statements of 4basebio PLC (“the Group”) for
the financial year ended 31 December 2025 have been prepared in accordance
with UK-adopted International Accounting Standards in conformity with the
requirements of the Companies Act 2006.
The consolidated financial statements comprise the results of 4basebio PLC,
4basebio S.L.U., 4basebio UK Limited, 4basebio Discovery Limited and 4basebio
Inc. (incorporated 7 April 2025) for the whole year (or, in the case of
4basebio Inc., from the date of incorporation).
The above summary has been extracted from the report and financial statements
and, accordingly, references to notes and page numbers may be incorrect.
Shareholders are advised to read the full version of the report and financial
statements which will be available from the Company’s website shortly.
3. Earnings per share
2025 2024
Numerator [in £'000]
Loss for the period (16,905) (12,333)
Denominator [number of shares]
Weighted average number of registered shares 15,507,339 13,116,570
Basic and diluted loss per share (£) (1.09) (0.94)
The calculation of the basic and diluted loss per share for continuing
operations was based on the weighted average number of shares as determined
above. The numerator is the loss after tax from continuing operations.
Outstanding share options have not been included in the calculation of the
diluted loss per share because they would be anti-dilutive since the business
is loss making.
4. Approval of the financial statements
The financial statements were approved by the Board of Directors and
authorised for issue on 19 May 2026.
Copyright (c) 2026 PR Newswire Association,LLC. All Rights ReservedRecent news on 4Basebio
See all newsREG-4basebio Plc: Final Results and Notice of AGM
AnnouncementREG-4basebio Plc: 4basebio Signs Clinical Supply Agreement to Support Phase II Clinical Trial
AnnouncementREG-4basebio Plc: Appointment of Chief Financial Officer and Board Changes
AnnouncementREG-4basebio Plc: 4basebio Launches Enzymatic ssDNA Platform
AnnouncementREG-4basebio Plc: Lease of Manufacturing Facility
Announcement